Analyst Expectations

MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4

amefika4 months ago03 mins

Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts expected, as the drugmaker prepares for the loss of exclusivity for several of its drugs. MSD reported fourth-quarter global sales of $16.4 billion, an increase of 5% from the same period in 2024….

Why elf Beauty (ELF) Stock Is Falling Today

amefika7 months ago03 mins

Shares of cosmetics company elf Beauty (NYSE:ELF) fell 3.6% in afternoon trading after the stock extended its negative momentum as the company reported mixed second-quarter results and issued a disappointing outlook for its full fiscal year, prompting a series of analyst downgrades and price target cuts. The cosmetics company’s revenue of $343.9 million missed analysts’…